BMTCN Test A Latest Update 2024-2025 Actual

EXAM ELABORATIONS Aug 30, 2025
Loading...

Loading document viewer...

Page 0 of 0

Document Text

BMTCN Test A Latest Update 2024-2025 Actual Exam from Credible Sources with 50 Questions and Verified Correct Answers Golden Ticket to Guaranteed A+ Verified by Professor

A patient had an allogeneic HSCT three years ago and now has type 4 posttransplant lymphoproliferative disease. How should the patient be treated?

  • Reduction of immunosuppressants
  • Aggressive chemotherapy
  • No interventions needed

D. Increased Immunosuppressants - CORRECT ANSWER: B. Aggressive

chemotherapy

Type 4 PTLD treated with aggressive chemotherapy has a good prognosis.

A patient reports facial swelling during the stem cell infusion. The nurse should immediately stop the infusion and anticipate an order for which medication?

  • Cryotherapy
  • Furosemide
  • Antihistamines

D. Oxygen - CORRECT ANSWER: C. Antihistamines

Urticaria, pruritus, facial or glottal edema are all signs of an allergic reaction. The nurse should stop the infusion and then administer antihistamines.

A patient should be instructed to manage oral mucositis by:

  • / 3
  • rinsing the mouth frequently with sodium bicarbonate.
  • requesting a prescription for "magic mouthwash".
  • using hydrogen peroxide rinses if there are no open lesions.
  • requesting a prescription for acyclovir rinses. - CORRECT ANSWER: A. rinsing the
  • mouth frequently with sodium bicarbonate.

The goals of mouth care and oral rinses with saline are to remove oral debris and microorganisms, provide mucosal hydration, and decrease inflammation and pain.

A patient who is diagnosed with acute myeloid leukemia two years after treatment for neuroblastoma is being evaluated for an allogeneic HSCT. Which medication most likely contributed to the secondary malignancy?

  • Cisplatin
  • Fludarabine
  • Cytarabine

D. Etoposide - CORRECT ANSWER: D. Etoposide

Topoisomerase II inhibitor-related AML usually appears 2-3 years after exposure to the drug. Etoposide is a topoisomerase II inhibitor.

A patient who received high-dose cyclophosphamide two days ago is now experiencing dyspnea, chest pain, orthopnea, cough, fever, and tachycardia. Which of the following is the patient most likely experiencing?

  • Paraneoplastic syndrome
  • Cardiotoxicity
  • Pulmonary embolism

D. Hyperthyroidism - CORRECT ANSWER: B. Cardiotoxicity

  • / 3

Cyclophosphamide cardiotoxicity presents with dyspnea, pleuritic chest pain, orthopnea, cough, fever, and tachycardia.

A patient with an overall grade +3 for acute graft-versus-host disease has a bilirubin

level of:

  • >15 mg/dL
  • 2-3 mg/dL
  • 3.1-6 mg/dL

D. 6.1-15 mg/dL - CORRECT ANSWER: D. 6.1-15 mg/dL

A patient with grade +3 for acute GVHD has a bilirubin level of 6.1-15 mg/dL.

A patient with lymphoma who received an HSCT has heart failure and arrhythmias. The

most likely cause is:

  • sirolimus.
  • high-dose cyclophosphamide.
  • cyclosporine.

D. long-term immunosuppressants. - CORRECT ANSWER: B. high-dose

cyclophosphamide.

High dose cyclophosphamide can cause cardiac side effects.

A pre-transplant patient asks about ABO compatibility with the donor. The nurse

explains that:

  • there is less risk of GVHD.
  • the likelihood of engraftment is increased.
  • it is not essential for success.
  • / 3

Download Document

Buy This Document

$30.00 One-time purchase
Buy Now
  • Full access to this document
  • Download anytime
  • No expiration

Document Information

Category: EXAM ELABORATIONS
Added: Aug 30, 2025
Description:

BMTCN Test A Latest Update 2024-2025 Actual Exam from Credible Sources with 50 Questions and Verified Correct Answers Golden Ticket to Guaranteed A+ Verified by Professor A patient had an allogenei...

Get this document $30.00